A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- Conditions
- Erythrodermic PsoriasisGeneralized Pustular Psoriasis
- Interventions
- Registration Number
- NCT06295692
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Brief Summary
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 19
- The study participant has a diagnosis of generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) at screening. For GPP, a diagnosis must be classified based on the criteria for diagnosis of GPP by the Japanese Dermatological Association (JDA); for EP, has a history of plaque-type psoriasis. In addition, has an involved body surface area (BSA) of lesion greater than or equal to (>=) 80 percent (%) at baseline
- Candidate for phototherapy or systemic treatment for psoriasis (either naive or history of previous treatment)
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and have a negative urine pregnancy test at Week 0 prior to administration of study intervention
- A male participant must agree not to plan to father a child while enrolled in this study or within 90 days after the last dose of study intervention
- A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study intervention
- The study participant has a total score of JDA severity index for GPP >=14 at baseline if participants have a diagnosis of GPP
- The study participant has a differential diagnosis of the erythroderma (for example, erythroderma caused by lymphoma or drug eruption) other than EP
- The study participant has a history of or current diagnosis or signs or symptoms of severe, progressive, or uncontrolled liver, renal; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- The study participant has a history of amyloidosis
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
- The study participant who doesn't meet the criteria of prior/current concomitant therapy and/or history/conditions of infections
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description JNJ-77242113- Participants With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) JNJ-77242113 Participants with GPP or EP will receive JNJ-77242113 tablet orally.
- Primary Outcome Measures
Name Time Method Percentage of Participants With Generalized Pustular Psoriasis (GPP) who Experience Treatment Success Based on Clinical Global Impression (CGI) Scale According to Japanese Dermatological Association (JDA) Total Score at Week 16 Week 16 GPP treatment success is defined as at least "minimally improved" rating according to total JDA score for GPP at Week 16. The CGI score is defined as 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = Worsened.
Percentage of Participants With Erythrodermic Psoriasis (EP) who Experience Treatment Success Based on CGI Scale at Week 16 Week 16 EP treatment success is defined as at least 'Minimally Improved' rating in CGI scale for EP at Week 16. The CGI score is defined as 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = Worsened.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Total Score of JDA Severity Index for GPP Baseline up to Week 156 The JDA Severity Index (JDA-SI) includes assessment of skin symptoms (area of erythema, area of erythema with pustules, and area of edema) and systemic symptoms/laboratory findings (fever, white blood cell count, C-reactive protein \[CRP\], serum albumin). The total score ranges from 0 to 17 with higher score indicating more severe disease .
Change From Baseline in Severity Classification of JDA Severity Index for GPP Baseline up to Week 156 Change from baseline in severity classification (mild, moderate and severe) of JDA severity index for GPP will be reported. The JDA-SI includes assessment of skin symptoms (area of erythema, area of erythema with pustules, and area of edema) and systemic symptoms/laboratory findings (fever, white blood cell count, CRP, serum albumin). The total score ranges from 0 to 17 and classifies disease severity as mild (0-6), moderate (7-10), or severe (11-17). Higher score indicate more severe disease.
Percentage of Participants who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) Up to Week 156 The IGA is 5-point scale assessing the severity of psoriasis, with scores cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Baseline up to Week 156 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: head, trunk, upper, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease .
Change From Baseline in Dermatology Life Quality Index (DLQI) Score Baseline up to Week 156 The DLQI is a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Percentage of Participants With GPP who Experience Treatment Success Based on CGI Scale According to JDA Total Score Over Time Up to Week 156 GPP treatment success is defined as at least "minimally improved" rating according to total JDA score for GPP. The CGI score is defined as 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = Worsened.
Change From Baseline in EuroQol-5 Dimension 5-Level (EQ-5D-5L) Baseline up to Week 156 The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems. The EQ-5D also includes a visual analog scale (EQ-VAS) that has endpoints labeled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today."
Percentage of Participants With EP who Experience Treatment Success Based on CGI Scale Over Time Up to Week 156 EP treatment success is defined as at least 'Minimally Improved' rating in CGI scale for EP. The CGI score is defined as 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = Worsened.
Change From Baseline in Body Surface Area (BSA) for EP Baseline up to Week 156 BSA is a commonly used measure of extent of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed.
Percentage of Participants who Achieve an IGA Score of Cleared (0) Up to Week 156 The IGA is 5-point scale assessing the severity of psoriasis, with scores cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants who Achieve a DLQI Score of 0 or 1 Up to Week 156 The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Percentage of Participants With Adverse Events (AEs) and Serious AEs Up to 160 weeks Percentage of participants with AEs and Serious AEs (SAEs) will be reported. An AE was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect.
Trial Locations
- Locations (12)
JR Sapporo Hospital
🇯🇵Hokkaido, Japan
Ichinomiya Municipal Hospital
🇯🇵Ichinomiya, Japan
Teikyo University Hospital
🇯🇵Itabashi Ku, Japan
Hospital of the University of Occupational and Enviromental Health
🇯🇵Kitakyushu-shi, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Nagoya City University Hospital
🇯🇵Nagoya, Japan
Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
🇯🇵Osaka, Japan
Tohoku University Hospital
🇯🇵Sendai, Japan
Dokkyo Medical University Hospital
🇯🇵Shimotsuga Gun, Japan
Tokyo Medical University Hospital
🇯🇵Shinjuku, Japan
Fujita Health University Hospital
🇯🇵Toyoake, Japan
Mie University Hospital
🇯🇵Tsu, Japan